About the VP-315 study
Before new investigational medications can be approved for public use, they must be tested in clinical research studies like this one. By joining the VP-315 study—you or your loved one are in good company—and helping researchers and scientists work towards a more hopeful future for everyone.
Why Participate?
The information learned from the study may help find new treatment options in the future for people with basal cell carcinoma. If you qualify for the study, you will receive the investigational treatment VP-315, with an injection directly into the tumor to cause cell death, which may offer a non-surgical option for patients suffering from skin cancer.
At the end of the study, all included BCC lesions will be surgically excised with a 3mm margin at no cost to participants.
What’s being tested?
In the VP-315 study, we are evaluating the safety and efficacy of an investigational drug called VP-315. VP-315 is designed to use the body’s own immune system to locate and cause cell death in basal cell carcinoma tumors through an injection directly into the tumor. The goal is to create an nonsurgical alternative in the treatment of basal cell carcinoma.
Dr. Neal Bhatia
Dermatologist
Therapeutics Dermatology
San Diego, CA
Clinical trials make a real difference
When you participate in a clinical study, you provide valuable information that could eventually lead to better treatment, and—with the right breakthrough—better outcomes. Take our short eight question survey to see if you or your loved one are a good fit. There is no obligation.